



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

IBRDC2 (m): 293T Lysate: sc-120934

BACKGROUND

p53 is the most commonly mutated gene in human cancer identified to date. Expression of p53 leads to inhibition of cell growth by preventing progression of cells from G₁ to S phase of the cell cycle. Most importantly, p53 functions to cause arrest of cells in the G₁ phase of the cell cycle following any exposure of cells to DNA-damaging agents. The MDM2 (murine double minute-2) protein was initially identified as an oncogene in a murine transformation system. MDM2 functions to bind p53 and block p53-mediated transactivation of cotransfected reporter constructs. The MDM2 gene is amplified in a high percentage of human sarcomas that retain wildtype p53 and tumor cells that overexpress MDM2 can tolerate high levels of p53 expression. Another p53 target protein is the p53-inducible RING finger protein (p53RFP), an auto-ubiquitinated protein acting as an E3 ubiquitin ligase. p53RFP receives ubiquitin from specific E2 ubiquitin-conjugating enzymes and transfers it to substrates that promote their degradation by the proteasome. p53RFP may mediate re-entry into the cell cycle.

REFERENCES

1. Vogelstein, B. 1990. Cancer. A deadly inheritance. *Nature* 348: 681-682.
2. Hollstein, M., et al. 1991. p53 mutations in human cancers. *Science* 253: 49-53.
3. Kastan, M.B., et al. 1991. Participation of p53 protein in the cellular response to DNA damage. *Cancer Res.* 51: 6304-6311.
4. Fakharzadeh, S.S., et al. 1991. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. *EMBO J.* 10: 1565-1569.
5. Oliner, J.D., et al. 1993. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. *Nature* 362: 857-860.
6. Chen, C.Y., et al. 1994. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. *Proc. Natl. Acad. Sci. USA* 91: 2684-2688.
7. Ng, C.C., et al. 2003. p53RFP, a p53-inducible RING-finger protein, regulates the stability of p21WAF1. *Oncogene* 22: 4449-4458.
8. Nakamura, Y., et al. 2004. Isolation of p53-target genes and their functional analysis. *Cancer Sci.* 95: 7-11.
9. SWISS-PROT/TrEMBL (Q7Z419). World Wide Web URL: <http://www.expasy.ch/sprot/sprot-top.html>

CHROMOSOMAL LOCATION

Genetic locus: Rnf144b (mouse) mapping to 13 A5.

PRODUCT

IBRDC2 (m): 293T Lysate represents a lysate of mouse IBRDC2 transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

APPLICATIONS

IBRDC2 (m): 293T Lysate is suitable as a Western Blotting positive control for mouse reactive IBRDC2 antibodies. Recommended use: 10-20 µl per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.